Technology and medicine has proven to be a profitable and socially beneficial marriage. Through research, development and manufacturing, the quality of healthcare has exponentially improved, particularly in the areas of pain reduction and cancer treatment. Theralase Technologies Inc. (TLT:CA) (TLTFF) , a Toronto-based medical developer and manufacturer of cold lasers, is working not just to treat cancer; but their latest technology actually seeks and destroys cancer cells.
Theralase Technologies has submitted a Clinical Trial Application (CTA) to Health Canada for its anti-cancer technology. Used to treat Non-Muscle Invasive Bladder Cancer (NMIBC), the anti-cancer technology is made possible by utilizing the company’s proprietary Theralase TLC-3200 Oncology Laser System to activate the Company’s lead Photo Dynamic Compound, TLD-1433.
“The submission of a CTA to Health Canada for NMIBC marks completion of another major milestone for the Company on our way to prove the safety, tolerability and efficacy of our anti-cancer technology in the destruction of numerous cancers, commencing with NMIBC,” said Theralase President and CEO Roger Dumoulin-White. “Pending approval of the CTA, ITA and REB, UHN will commence enrolling and treating patients afflicted with this deadly disease.”
The Hopeful Future of Medicine
Theralase’s anti-cancer technology operates its development and research within two divisions: Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). TLT, approved by the FDA and Health Canada, designs, manufactures and markets patented super-pulsed laser technology that eliminates pain, reduces inflammation and accelerates the healing of tissue for various nerve, muscle and joint conditions. PDT, also referred to as photochemotherapy, researches and develops Photo Dynamic Compounds that localize cancer cells. When Theralase’s laser light is activated, the cancer cells are destroyed.
Along with Health Canada, Theralase has submitted applications to the UHN Research Ethics Board and the Health Canada Investigational Testing Authorization. Approval from these organizations will allow Theralase to conduct a Phase Ib clinical study at Princess Margaret Cancer Center, University Health Network. The study will test safety and tolerability of the anti-cancer technology on patients diagnosed with NMIBC. Each year in the United States, 50,000 men and 16,000 women are diagnosed with bladder cancer.
Theralase’s anti-cancer technology, once advanced to clinical trials, brings medicine one step closer to relieving patients suffering from various cancers.
For more information about Theralase’s medical research and development, visit www.theralase.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer